“Skinny Labeling: Origins, Evolution, and Key Decisions,” Pharmaceutical Executive

In an article published on Pharmaceutical Executive on January 7, 2026, Principal Leanne Rakers and Associate Jeffrey Lin discussed skinny labeling and how manufacturers utilize it when seeking FDA approval, and how these labels can lead to induced infringement.

Rakers and Lin state, “Legal disputes have intensified as brand-name manufacturers assert method-of-use patents, raising the question: Can generics be liable for induced infringement despite carve-outs?”

They outlined the key cases and their implications, as well as key takeaways for implementing skinny labels, specifying, “Skinny labels are lawful but are not absolute shields. They must be carefully drafted and supported by compliant marketing practices. Generics should avoid marketing their products as equivalent to brand-name products, at least for now.”

To read the full article online, click here.